Impact of detecting potentially serious incidental findings during multi-modal imaging:[version 3; peer review: 2 approved, 1 approved with reservations] by Gibson, Lorna M et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact of detecting potentially serious incidental findings during
multi-modal imaging
Citation for published version:
Gibson, LM, Littlejohns, TJ, Adamska, L, Garratt, S, Doherty, N, Wardlaw, JM, Maskell, G, Parker, M,
Brownsword, R, Matthews, PM, Collins, R, Allen, NE, Sellors, J & Sudlow, C 2018, 'Impact of detecting
potentially serious incidental findings during multi-modal imaging', Wellcome Open Research , vol. 2, pp.
114. https://doi.org/10.12688/wellcomeopenres.13181.1
Digital Object Identifier (DOI):
10.12688/wellcomeopenres.13181.1
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Wellcome Open Research
Publisher Rights Statement:
© 2017 Gibson LM  . This is an open access article distributed under the terms of the  , which Copyright: et al
Creative Commons Attribution Licence permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 11. May. 2020
 Open Peer Review
Discuss this article
 (0)Comments
RESEARCH ARTICLE
Impact of detecting potentially serious incidental findings during
 multi-modal imaging [version 1; referees: 1 approved, 1
approved with reservations]
Lorna M Gibson ,       Thomas J Littlejohns , Ligia Adamska , Steve Garratt ,
     Nicola Doherty , UK Biobank Imaging Working Group, Joanna M Wardlaw ,
       Giles Maskell , Michael Parker , Roger Brownsword , Paul M Matthews ,
     Rory Collins , Naomi E Allen , Jonathan Sellors , Cathie LM Sudlow1,3*
Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
UK Biobank Coordinating Centre, Stockport, UK
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
Royal Cornwall Hospitals NHS Trust, Cornwall, UK
Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
The Dickson Poon School of Law, King’s College London, London, UK
Division of Brain Sciences, Department of Medicine, Hammersmith Hospital, Imperial College London, London, UK
 Equal contributors
Abstract
: There are limited data on the impact of feedback of incidentalBackground
findings (IFs) from research imaging.  We evaluated the impact of UK Biobank’s
protocol for handling potentially serious IFs in a multi-modal imaging study of
100,000 participants (radiographer ‘flagging’ with radiologist confirmation of
potentially serious IFs) compared with systematic radiologist review of all
images.
: Brain, cardiac and body magnetic resonance, and dual-energy x-rayMethods
absorptiometry scans from the first 1000 imaged UK Biobank participants were
independently assessed for potentially serious IFs using both protocols. We
surveyed participants with potentially serious IFs and their GPs up to six
months after imaging to determine subsequent clinical assessments, final
diagnoses, emotional, financial and work or activity impacts.
: Compared to systematic radiologist review, radiographer flaggingResults
resulted in substantially fewer participants with potentially serious IFs
(179/1000 [17.9%] versus 18/1000 [1.8%]) and a higher proportion with serious
final diagnoses (21/179 [11.7%] versus 5/18 [27.8%]). Radiographer flagging
missed 16/21 serious final diagnoses (i.e., false negatives), while systematic
radiologist review generated large numbers of non-serious final diagnoses
(158/179) (i.e., false positives). Almost all (90%) participants had further clinical
assessment (including invasive procedures in similar numbers with serious and
non-serious final diagnoses [11 and 12 respectively]), with additional impact on
emotional wellbeing (16.9%), finances (8.9%), and work or activities (5.6%).
: Compared with systematic radiologist review, radiographerConclusions
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 : Compared with systematic radiologist review, radiographerConclusions
flagging missed some serious diagnoses, but avoided adverse impacts for
many participants with non-serious diagnoses. While systematic radiologist
review may benefit some participants, UK Biobank’s responsibility to avoid both
unnecessary harm to larger numbers of participants and burdening of
publicly-funded health services suggests that radiographer flagging is a
justifiable approach in the UK Biobank imaging study. The potential scale of
non-serious final diagnoses raises questions relating to handling IFs in other
settings, such as commercial and public health screening.
 Cathie LM Sudlow ( )Corresponding author: cathie.sudlow@ed.ac.uk
  : Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Software, Visualization, Writing –Author roles: Gibson LM
Original Draft Preparation, Writing – Review & Editing;  : Data Curation, Formal Analysis, Methodology, Writing – Review & Editing; Littlejohns TJ
: Data Curation, Writing – Review & Editing;  : Data Curation, Writing – Review & Editing;  : Project Administration; Adamska L Garratt S Doherty N
: Supervision, Writing – Review & Editing;  : Writing – Review & Editing;  : Writing – Review & Editing; Wardlaw JM Maskell G Parker M
: Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing; Brownsword R Matthews PM
: Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing;  : Conceptualization, Funding Acquisition,Collins R Allen NE
Methodology, Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Supervision, Writing – Review & Editing;  :Sellors J Sudlow CL
Conceptualization, Data Curation, Funding Acquisition, Methodology, Supervision, Writing – Review & Editing
 LMG: Member of the UK Biobank Imaging Working Group. UK Biobank Imaging Consultant, University of Edinburgh. TJL:Competing interests:
UK Biobank Epidemiologist, University of Oxford. LA: UK Biobank Data Analyst, University of Oxford. SG: Member of the UK Biobank Imaging
Working Group. Senior Project Manager of UK Biobank. ND: Senior Clinical Study Administrator of UK Biobank. JMW: Advised on imaging
protocols for the UK Biobank imaging study. Currently analysing UK Biobank brain imaging data. GM: Member of the UK Biobank International
Scientific Advisory Board. MP: Director of Ethox, University of Oxford. Ethox provides independent advice on ethical matters to UK Biobank. RB:
None currently. Former chair of the UK Biobank Ethics and Governance Council. PMM: Chair of the UK Biobank Imaging Working Group, Member
of UK Biobank Steering Committee. RC: CEO and Principle Investigator of UK Biobank. Chair of UK Biobank Steering Committee. Member of the
UK Biobank Imaging, Enhancements, Follow-up and Outcomes and Infectious Diseases Working Groups. NEA: Member of UK Biobank Steering
Committee, UK Biobank Imaging, Enhancements, Follow-up and Outcomes and Infectious Diseases Working Groups. UK Biobank Senior
Epidemiologist. JS: UK Biobank Legal Counsel. CLMS: Member of UK Biobank Steering Committee, and UK Biobank Imaging, Enhancements,
and Follow-up and Outcomes Working Groups. UK Biobank Chief Scientist.
 Gibson LM, Littlejohns TJ, Adamska L   How to cite this article: et al. Impact of detecting potentially serious incidental findings during
 Wellcome Open Research 2017,  :114 (doi: multi-modal imaging [version 1; referees: 1 approved, 1 approved with reservations] 2
)10.12688/wellcomeopenres.13181.1
 © 2017 Gibson LM  . This is an open access article distributed under the terms of the  , whichCopyright: et al Creative Commons Attribution Licence
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 This work was supported by the Wellcome Trust [107190]. UK Biobank is funded by the Wellcome Trust, Medical ResearchGrant information:
Council, Department of Health, Scottish Government, Northwest Regional Development Agency, Welsh Assembly Government, British Heart
Foundation, and Diabetes UK.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 30 Nov 2017,  :114 (doi:  ) First published: 2 10.12688/wellcomeopenres.13181.1
Page 2 of 19
Wellcome Open Research 2017, 2:114 Last updated: 11 JAN 2018
Introduction
UK Biobank (www.ukbiobank.ac.uk) is a major resource for 
research into the determinants of a wide range of serious and 
life-threatening diseases, to improve their prevention, diagnosis 
and treatment1. It is a prospective study which recruited 500,000 
men and women aged 40–69 across the UK between 2006 and 
20101. It includes extensive questionnaire and physical meas-
urement data from the baseline visit, biological samples (with 
genotyping and biomarker assay data), longitudinal follow-up 
data from national health-related datasets and additional informa-
tion from remote monitoring and web-based questionnaires.
The UK Biobank imaging study aims to perform brain, cardiac 
and body magnetic resonance imaging (MRI), dual-energy 
x-ray absorptiometry (DXA) and carotid Doppler ultrasound in 
100,000 UK Biobank participants in dedicated imaging centres 
over seven years (http://imaging.ukbiobank.ac.uk/). By November 
2017, over 20,000 participants had attended an imaging assess-
ment visit (http://imaging.ukbiobank.ac.uk/), making it already 
the world’s largest ever multi-modal imaging study2.
Incidental findings (IFs), defined as ‘findings discovered in the 
course of research that are beyond the aims of the study,’3 are a 
predictable consequence of much research, and studies need 
appropriate protocols for handling them (https://wellcome.ac.uk/
funding/managing-grant/wellcome-trust-policy-position-health-
related-findings-research/)4. IFs are particularly pertinent to the 
UK Biobank imaging study given its large scale and the potential 
seriousness of IFs that may be detected. While clinical care and 
screening programmes aim to provide clinical benefit to patients, 
research studies have the primary aim of producing generalisable 
knowledge. Nevertheless, while research studies do not aim to 
benefit participants directly, they are obliged to minimise potential 
harms to participants and the wider public. Hence, although the UK 
Biobank imaging study aims to collect research data, rather than 
to detect or diagnose serious disease, it does require a protocol to 
handle IFs should they arise.
The UK Biobank imaging IFs protocol was developed as a prag-
matic, scalable process, aiming to produce the best possible 
resource for biomedical research while minimising any poten-
tial harms for 100,000 largely asymptomatic UK Biobank par-
ticipants. UK Biobank reviewed current practice, the extensive 
literature3,5,6 and relevant published guidance (https://www.rcr.
ac.uk/publication/management-incidental-findings-detected- 
during-research-imaging), sought independent legal advice, 
and consulted with its independent Ethics and Governance 
Council, the UK’s Royal College of Radiologists and Society 
and College of Radiographers, funders, relevant experts and 
leading imaging research projects (including the Multi-Eth-
nic Study of Atherosclerosis [http://www.hopkinsmedicine.
org/heart_vascular_institute/clinical_trials/preventive/mesa.
html], the Reykjavik Heart Study [http://www.hjartarannsokn.
is/index.aspx?GroupId=406], the Rotterdam Scan Study7 and the 
German National Cohort [http://nako.de/])2. Key contextual fac-
tors considered were the non-clinical setting of the imaging visit, 
in which the scanning sequences are optimised for research use 
rather than clinical diagnosis, and the nature of the participants’ 
existingconsent (in particular the approach to the feedback of IFs). 
However, cost effectiveness was not considered relevant2.
The UK Biobank imaging IFs protocol involves feedback to 
participants and their general practitioners (GPs) when a radiog-
rapher observes a potentially serious IF during image acquisition 
that is subsequently confirmed by a specialist radiologist. UK 
Biobank defines a potentially serious IF for these purposes as one 
indicating the possibility of a condition which, if confirmed, would 
carry a real prospect of seriously threatening life span, or of having 
a substantial impact on major body functions or quality of life.
The need for evidence to inform IFs policy
Limited data exist on the impact of feedback of IFs on partici-
pants8 and health services9, and on how these vary by different 
policies for handling IFs. Most published data on opinions of 
receiving such feedback are based on hypothetical scenarios, 
rather than studies of research participants who have actually 
received feedback10–12. It is often assumed that early observation 
on imaging of presumed disease (prior to clinical presentation) is 
inevitably beneficial, but data on final clinical diagnosis and the 
impact of feedback of IFs are scarce13. Such data would inform 
debates about these assumptions, and the design of appropriate, 
acceptable protocols to handle IFs detected in research, public 
health screening or commercial imaging settings.
In this evaluation of the first 1000 participants in the UK Biobank 
imaging study, we assessed the number and types of potentially 
serious IFs detected and their final clinical diagnoses, comparing 
the UK Biobank imaging IFs protocol with systematic radiologist 
review of all of the images. We also assessed the impact of providing 
feedback about potentially serious IFs on participants, their friends, 
families and health services, with respect to: clinical assessments 
undertaken; emotional wellbeing, finances, work and daily activi-
ties; and participants’ and their general practitioners’(GP) opinions 
about receiving feedback.
Methods
Participants
Existing participants of the UK Biobank cohort study who lived 
within about 100 miles of UK Biobank’s first imaging centre 
in Stockport were invited to participate in the UK Biobank 
imaging study. The invitation contained a link to the UK Biobank 
imaging study website (http://imaging.ukbiobank.ac.uk/), and 
willing participants were asked to telephone the Participant 
Recruitment Centre where they could ask questions about the 
study and answer pre-screening safety questions. Participants 
were excluded if they had metal inside their body or an implanted 
medical device which could create imaging artefacts or pose a 
risk during MRI, if they were likely to find it difficult to lie still, 
or if they were unlikely to tolerate the imaging due to known 
claustrophobia.
Consent
All participants received written information about the imag-
ing study, including details about the UK Biobank imaging IFs 
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protocol, and provided consent before taking part, including 
consent for UK Biobank to inform them and their GP if a 
potentially serious IF was identified (Supplementary File 1). We 
surveyed all participants with a questionnaire two days after their 
imaging assessment to assess their understanding of the informa-
tion and consent process (http://www.ukbiobank.ac.uk/resources/).
Imaging
Participants underwent a 30 minute brain MRI (3.0 Tesla Skyra 
scanner, Siemens, Erlangen, Germany), a 30 minute non-contrast 
cardiac and body MRI (1.5 Tesla Aera scanner, Siemens, 
Erlangen, Germany) from neck to knees (Supplementary File 2), 
and a 15 minute DXA scan (iDXA, General Electric, New York, 
United States of America) of whole body, lumbar spine and hip, 
with lateral vertebral fracture assessment. Participants also under-
went carotid doppler ultrasound, but this was not considered to 
have the potential to yield potentially serious IFs (Supplementary 
File 3). Imaging protocols were optimised for research purposes 
and did not constitute standard diagnostic examinations.
List of potentially serious IFs
UK Biobank consulted radiologists, reviewed the literature, and 
considered the German National Cohort’s list of imaging IFs14 to 
develop a list of IFs considered to be potentially serious, as well 
as examples of those not considered serious (Supplementary 
File 3). Both radiographers and reporting radiologists used this 
list in conjunction with UK Biobank’s definition of a potentially 
serious IF when judging whether any observed IF was potentially 
serious or not.
Two protocols for handling IFs
Images from the first 1000 participants were assessed using two 
protocols which ran simultaneously. Under the UK Biobank 
IFs protocol (‘radiographer flagging’), if a radiographer noticed 
a potentially serious IF during image acquisition and quality 
assessment, the relevant set of images was flagged for subse-
quent review by a radiologist. Under ‘systematic radiologist 
review’, all images were systematically reviewed by a radiologist. 
Radiographers were trained in the relevant imaging protocols but 
did not receive specific training in image interpretation. Radiolo-
gists and radiographers were aware of the comparison study, but 
were blind to each other’s opinions. To aid image interpretation, we 
provided reporting radiologists with data collected during the 
imaging visit on the participant’s age, sex, body mass index, 
self-reported smoking status, alcohol consumption, medical 
history and medications.
Within a few weeks of their imaging visit, we wrote to all 
participants who had a potentially serious IF reported by a radi-
ologist, whether it had been both flagged by a radiographer and 
confirmed by a radiologist (radiographer flagging) or detected 
by a radiologist during systematic review of all images (system-
atic radiologist review). We explained that a potentially serious 
abnormality (or, sometimes, abnormalities) had been observed, 
and advised the participant to visit his/her GP for advice about any 
further action required (Supplementary File 4). We also wrote 
to these participants’ GPs, providing a copy of the radiologist’s 
report and, if requested, copies of the relevant scans 
(Supplementary File 5).
Questionnaires to participants with potentially serious IFs 
and their GPs
We surveyed participants with potentially serious IFs approxi-
mately six weeks after writing to them and their GP and 
approximately six months after their imaging visit to assess 
the impact of this information. Both participant questionnaires 
collected data on clinical assessment (blood tests, imaging, 
specialty referral, changes in medication, invasive procedures and 
operations), final diagnoses, and opinions on receiving feedback 
and participating in the imaging study, with additional questions 
at six months on emotional wellbeing, insurance, finances, work 
and activities. We also surveyed GPs at six months about clinical 
assessments, final diagnoses (including copies of any relevant 
clinical correspondence) and their perceptions of the impact on 
their patients of receiving feedback (http://www.ukbiobank.ac.uk/
resources/). We reconciled multiple responses on similar items 
from the three questionnaires by prioritising ‘yes’ responses and 
included data from coding of free text responses.
Determining final clinical diagnoses
A consultant physician and an experienced speciality clinical 
radiology trainee independently classified final diagnoses for 
each participant who received feedback about a potentially 
serious IF, by reviewing all available questionnaire data together 
with additional relevant clinical information from further corre-
spondence or telephone calls with the participant and/or their GP. 
Working from the definition of a potentially serious IF, we clas-
sified final clinical diagnoses as: serious if they were likely to 
significantly threaten lifespan or have a major impact on quality of 
life or major body functions; not serious if this was not the case, 
or if the available data suggested that the diagnosis was already 
known; and uncertain if there were insufficient data to classify 
as serious or not. We classified participants with more than one 
potentially serious IF according to their most serious final 
diagnosis. We calculated the percentage of participants in whom 
both classifying doctors agreed on the classification, resolving 
disagreements through discussion and mutual consensus.
Qualitative study
To provide additional context, UK Biobank commissioned a 
social research company (TNS-BMRB; www.tns-bmrb.co.uk) to 
conduct a parallel qualitative study. This aimed: (1) to explore 
participants’ understanding of and opinions about the proc-
ess of consent relating to feedback of potentially serious IFs 
through deliberative group discussions with two groups of around 
10 participants each (a more and a less affluent group) prior to 
their imaging assessment; and (2) to assess views on the process 
and impact of receiving feedback through one-to-one interviews 
with 15–20 participants (including more and less affluent male 
and female participants) with IFs on different imaging modali-
ties, and with both serious and non-serious final clinical diagnoses. 
Further details of the methods of recruitment, interview content 
and qualitative analysis methods are available at http://www.
ukbiobank.ac.uk/resources/.
Statistical analyses
We summarised data from questionnaires as counts and propor-
tions. We compared groups using chi-squared or Fisher’s exact 
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tests for proportions and Student’s independent t-test for 
continuous variables. We considered p values of <0.05 to be 
statistically significant and analysed data using Microsoft Excel 
2013 and SPSS Statistics version 21.
Ethics approval
UK Biobank obtained approval specifically for the imaging 
study, participant information and consent materials and this 
evaluation, including surveying participants and their GPs 
(North West Research Ethics Committee, Reference Number: 
11/NW/0382).
Results
The first 1000 eligible participants were imaged between April 
and September 2014. Their mean age was 62 (range 44–77) years, 
and 524 (52.4%) were female. Each MRI imaging modality was 
conducted in >94% participants, and DXA in >99% (Figure 1).
Understanding of consent
Around 60% of the first 1000 participants (607/1000) completed 
the questionnaire assessing understanding of consent. The vast 
majority correctly understood that they would not receive their 
scans or results at the end of the imaging visit (540/607, 86.7%) 
Figure 1. Participant flowchart. MRI = magnetic resonance imaging, DXA = dual energy x-ray absorptiometry. 168 participants had 
incomplete imaging: 18 underwent DXA but not MRI due to safety issues, 50 did not complete all MRI (28 due to claustrophobia, 13 due to 
scanner failure, nine for other reasons). 2Final diagnosis assigned to participants with more than one potentially serious incidental finding was 
the most serious (serious>uncertain>not serious). 3Three of these participants had uncertain final diagnoses, see Supplementary File 7.
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and that they would not be told about any potentially serious IF 
during the visit (89.0%), but around a quarter incorrectly thought 
that they could choose whether or not to be informed about any 
potentially serious IF (158/607, 26.0%) (Supplementary File 6).
Potentially serious IFs
Radiographers flagged 66 potentially serious IFs in 66 (6.6%) 
participants. Of these, 18 (1.8%) were confirmed as potentially 
serious by radiologists. Radiologists detected potentially serious 
IFs in 179 (17.9%) participants (Figure 1), who included the 
18 participants with potentially serious IFs flagged by radiog-
raphers. Participants with potentially serious IFs were slightly 
older than those without (mean age 63 versus 61 years, p=0.03), 
but their sex distribution did not differ significantly (55.3% vs 
51.8% female, p=0.4).
Final diagnoses
Data on final diagnoses were available from one or more ques-
tionnaires, clinical correspondence and/or telephone contact in 
176/179 (98.3%) participants. The two doctors agreed on the 
per-participant classification of final diagnoses in 172/179 
(96.1%) cases. The seven cases of initial disagreement were readily 
resolved by discussion.
A higher proportion of participants with potentially serious IFs 
had serious final diagnoses (i.e. true positives) with radiogra-
pher flagging (5/18, 27.8%) than with systematic radiologist 
review (21/179, 11.7%, Figure 1, Table 1). A higher proportion 
and substantially greater absolute number had non-serious final 
diagnoses (i.e. false positives) with systematic radiologist review 
(158/179, 88.3%) than radiographer flagging (13/18, 72.2%). 
However, radiographer flagging missed 16 of the 21 participants 
with a serious final diagnosis detected by systematic radiologist 
review (i.e. false negatives) (Figure 1, Table 1, Supplementary 
File 7).
The numbers and proportions of participants with potentially 
serious IFs and with serious versus non-serious final diag-
noses varied substantially by imaging modality. Most of the 158 
false positives generated by systematic radiologist review were 
identified on cardiac or body MRI (54 on cardiac and 65 on body 
[mainly abdominal] MRI; Table 1). Participants with poten-
tially serious IFs from brain and cardiac MRI were more likely 
to have a serious final diagnosis (around half under radiographer 
flagging, and 20% under systematic radiologist review) than those 
with potentially serious IFs from the other imaging modalities 
(Table 1).
Table 1. Clinical seriousness of final diagnoses of 179 participants by detection method and imaging 
modality.
Method of detection and 
imaging modality
Clinical seriousness of final 
diagnosis (n participants) % of 1000 imaged 
participants with 
≥ 1 PSIF detected
% of participants 
in whom a PSIF 
predicted a serious 
final diagnosisSerious Non-serious1 Total
Radiographer flagging
      Brain MRI 2 2 4 0.4 50.0
      Cardiac MRI 3 2 5 0.5 60.0
      Body MRI 0 8 8 0.8 0.0
      DXA 0 1 1 0.1 0.0
      > 1 modality 0 0 0 0.0 0.0
Total (any modality) 5 13 18 1.8 27.8
Systematic radiologist 
review
      Brain MRI 4 14 18 1.8 22.2
      Cardiac MRI 13 54 67 6.7 19.4
      Body MRI 3 65 68 6.8 4.4
      DXA 1 10 11 1.1 9.1
      > 1 modality2 0 15 15 1.5 0.0
Total (any modality) 21 158 179 17.9 11.7
PSIF = potentially serious incidental finding, MRI = magnetic resonance imaging, DXA = dual energy X-ray absorptiometry
1 Includes three participants whose final diagnoses remained uncertain as of April 2016: one participant with a lung 
nodule was still under assessment; another participant with a lung nodule had been diagnosed with lymphoma, but it 
remained unclear whether the nodule was related to the lymphoma or not; and we were unable to contact one participant 
to determine the final diagnosis of DXA appearances suggesting a crush fracture.
2 Fifteen participants had more than one non-serious final diagnosis arising from more than one modality.
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Systematic radiologist review generated 217 potentially serious 
IFs in 179 participants. More than one potentially serious IF 
occurred in 33 participants (28 had two and five had three), 
although no participant had more than one serious final diag-
nosis. The 21 serious final diagnoses included aortic aneurysms, 
tumours, structural and functional cardiac disease, and osteoporotic 
fractures, while non-serious final diagnoses comprised benign 
lesions, diagnoses already known to the participant and/or their 
GP, and suspected lesions which were not confirmed.
Follow-up questionnaires
Each of the three follow-up questionnaires was returned for 
≥70% of 179 participants with a potentially serious IF; at least 
one questionnaire was returned for 93.3% and all three for 45.8% 
(Table 2). Denominators varied for different types of clinical 
assessment and impact due to different proportions of completed 
responses to the relevant questions (Table 3).
Clinical assessment
All participants with follow-up questionnaire data had con-
tacted their GP. Almost all had some form of clinical assessment 
(153/170 [90.0%]), most frequently blood tests (29.4%), fur-
ther imaging (78.8%) or specialist referral (64.1%), with smaller 
proportions having other tests (8.8%), change of medication 
(10.5%) or an invasive procedure or operation (14.2%) (Table 3). 
The proportions having each type of clinical assessment were 
generally higher for those with a serious compared with non- 
serious final diagnosis, particularly medication changes (44.4% 
serious versus 6.3% non-serious) and invasive procedures (61.1% 
versus 8.3%). However, the absolute numbers having clinical 
assessment were far higher among the many more participants 
with non-serious final diagnoses. Of the 153 participants reporting 
some form of clinical assessment, 133 had a non-serious final 
diagnosis, suggesting that further clinical assessment might not 
have been necessary (Table 3).
Of particular note, similar absolute numbers of participants 
had invasive, potentially harmful, procedures irrespective of 
whether their final diagnosis was considered to be serious (n=11) 
or non-serious (n=12) (Supplementary File 8). The clinical 
management of the participants with a serious final diagnosis is 
summarised in Supplementary File 9.
Impact on participants
Feedback about a potentially serious IF also had an impact 
(presumed to be adverse) on participants’ emotional wellbe-
ing (21/124, 16.9%), insurance or finances (11/124, 8.9%), and 
work or activities of daily living (7/124, 5.6%). The proportion 
of participants reporting an impact on emotional wellbeing was 
higher among those with a serious final diagnosis, but the abso-
lute numbers were higher among those with a non-serious final 
diagnosis, for whom these impacts could be considered to 
constitute net harm (Table 3). In addition to the 21 reporting 
an impact on emotional wellbeing in response to the relevant 
survey question, participants and/or their GPs spontaneously men-
tioned worry within questionnaire free-text responses for a further 
62 participants (examples shown in Box 1).
Box 1. QUOTATIONS FROM PARTICIPANTS AND THEIR 
GENERAL PRACTITIONERS (GP)
Participant with a non-serious final diagnosis, six-week 
questionnaire: “Better to know, but I did feel anxious for a few 
weeks.”
Participant with a serious final diagnosis, six-month 
questionnaire: “Life has been a physical & emotional roller-
coaster since then, both for myself, family & friends. A serious 
risk of death on the operating table, and considering the 
consequences for my wife. All-in-all, I feel as if I was mugged by 
medical technology.”
GP of a participant with a non-serious final diagnosis: “[The 
patient] was asymptomatic. In normal practice no investigation 
would be performed - this has led to unnecessary anxiety and 
tests.”
GP of a participant with a non-serious final diagnosis: “Concerns 
over use of health resources regarding this. Using GP and 
secondary care time with potential [upper gastrointestinal 
endoscopy] +/- associated risks of this procedure. This for 
symptoms that the patient is not too concerned with at present.”
Most participants receiving feedback reported no change in their 
health since the imaging visit (104/124, 83.9%). Similar abso-
lute numbers among those with serious versus non-serious final 
diagnoses had worse health (6/15, 40.0% versus 5/109, 4.6%), 
while a few of those with a non-serious final diagnosis (but 
none with a serious final diagnosis) reported better health (9/109, 
8.3%, Table 3).
Opinions on receiving feedback
Almost all participants reported being glad to be told about their 
potentially serious IF (142/145 (97.7%) (Table 3). Nonethe-
less, GPs who responded reported that a higher proportion of 
participants had experienced negative versus positive impact 
on emotional wellbeing (38/99, 38.4% versus 16/99, 16.2%), 
with most of the negative impact occurring among those with 
non-serious final diagnoses (Table 3). GPs also spontane-
ously highlighted concerns about use of health resources to 
manage asymptomatic people within their free-text questionnaire 
responses (Box 1). However, the responding GPs believed that a 
slightly higher proportion of participants had experienced net 
benefit compared to net harm (51/86, 59.3% versus 35/86, 40.7%).
Table 2. Available questionnaires returned by 179 
participants and their GPs.
n participants 
(%)
Six-week participant questionnaire 132 (74)
Six-month participant questionnaire 125 (70)
Six-month GP questionnaire 125 (70)
At least one questionnaire returned1 167 (93)
All three questionnaires returned 82 (46)
1At least one of a six-week participant, six-month participant, or 
six-month GP questionnaire
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Figure 2. Extrapolation of this study’s findings to the 100,000 UK Biobank imaging study participants. MR = magnetic resonance, 
IF = incidental finding.
A higher proportion of responding GPs (61/94, 64.9%) than par-
ticipants (55/149, 36.9%) thought participants should be always 
told about a potentially serious IF (Table 3). Since participants 
were asked both at six weeks and at six months about this, we 
were able to assess whether the answers of 105 participants who 
responded on both occasions changed over time. While 69 had 
consistent responses, 36 changed their views (n=21, Table 3: 
footnote 10).
Results of the qualitative study
Deliberative group discussions about consent involved a group of 
10 ‘more affluent’ participants (Townsend score <-2, four female, 
mean age 61, SD 9.1 years), and a group of 11 ‘less affluent’ par-
ticipants (Townsend score >0, six female, mean age 66 years). 
One-to-one interviews involved an additional 21 participants 
who received feedback about a potentially serious IF (13 ‘more 
affluent’, 13 female, mean age 66 years). Analysis of the inter-
view data revealed that participants were motivated to attend the 
imaging study by altruism, to experience MRI scanning first- 
hand (in case they needed to attend for investigations for a 
medical concern later in life), and to receive feedback about 
potentially serious IFs. Participants could not always recall precise 
details of the consent process with respect to feedback of IFs,  but 
they were generally unconcerned about this as they trusted UK 
Biobank to act appropriately. One-to-one interviews further dem-
onstrated that the implications of receiving feedback were not fully 
understood until after the event, that feedback resulted in short-
term anxiety, and that participants tended to assume the worst on 
receiving feedback; indeed, some were surprised that the final diag-
nosis might be non-serious, having anticipated a diagnosis of can-
cer, an aneurysm or a serious heart condition. Further details of 
the qualitative study results are available at http://www.ukbiobank.
ac.uk/resources/.
Discussion
Compared to systematic review of images by radiologists, the 
UK Biobank IFs protocol (radiographer flagging) resulted in 
approximately 10-fold fewer participants with non-serious 
diagnoses (i.e., false positives), but missed 16/21 potentially serious 
IFs that were diagnosed ultimately as a serious disease (i.e. false 
negatives).
Extrapolation of our results to the 100,000 participants who 
will be imaged by UK Biobank over the next few years suggests 
that systematic radiologist review would generate 15,800 false 
positives, compared with 1,300 under the UK Biobank IF proto-
col (radiographer flagging), and would detect serious diagnoses 
in 2,100 participants compared with 500 under radiographer 
flagging (Figure 2).
Systematic radiologist review in our study generated a preva-
lence of potentially serious IFs of 17.9%. The prevalence in other 
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whole-body MRI studies of healthy populations ranged from 
12.8% to 57.6%15–18. Since those studies used similar MRI 
sequences applied to similar tissue volumes, variations in preva-
lence are most likely to have arisen from differences in the 
definition of IFs, or in the age and other characteristics of the 
imaged populations.
Almost all participants with potentially serious IFs had subsequent 
clinical assessment, resulting in large numbers of investigations, 
referrals and procedures. Many of these were, with hindsight, 
unnecessary, with risk of direct harm as well as cost implica-
tions. Impact on emotional wellbeing, insurance or finances, and 
on work or daily activities were reported by a higher proportion 
of participants with serious final diagnoses, but affected a higher 
absolute number of participants without serious final diagnoses. In 
keeping with these results, over half of participants in the Study of 
Health in Pomerania who received feedback of an IF detected on 
whole-body MRI reported psychological distress8.
Only around one-third of our participants believed that partici-
pants should always be told about potentially serious IFs. Similar 
proportions of participants with serious and participants with 
non-serious final diagnoses expressed this opinion. However, 
almost a quarter of participants changed their opinion over the few 
months between the six-week and six-month questionnaires on 
whether participants should or should not be able to choose to 
receive feedback of an IF (Table 3: footnote 10), illustrating the 
complexities in interpreting opinions on this issue.
Our results reinforce the need for clarity in the information 
provided to participants about the feedback policy before they 
consent to imaging research studies. While participants’ under-
standing of what they had consented to was generally good, a sub-
stantial minority (around a quarter) incorrectly thought that they 
could choose whether or not to receive feedback. The information 
materials for the UK Biobank imaging study now further empha-
size the difference between research and clinical diagnostic 
imaging, that the imaging is not a ‘health check,’ that not all seri-
ous disease will be detected, and that some potentially serious 
IFs will prove to be non-serious with further investigations 
(http://imaging.ukbiobank.ac.uk/).
The findings of this study are of practical ethical importance. 
Considering the ethical principle of non-maleficence, our data 
suggest that feeding back potentially serious IFs which turn out 
not to be serious (false positives) can make some participants 
worse off, through exposure to the inconvenience, worry and 
potential harms of clinical assessments, including invasive 
procedures. Feedback of false positives also results in wider 
harm through the unnecessary use of publicly-funded health serv-
ices. Missing a serious disease (false negative) does not make 
participants worse off compared to their status before receiv-
ing feedback of a potentially serious IF; rather, it fails to make 
participants better off. The choice between protocols becomes 
more complex when other ethical principles, particularly benefi-
cence, are considered. While the literature about IFs sometimes 
argues that feedback is inevitably beneficial19, the balance of 
potential benefits and harms of earlier diagnosis (of IFs which 
are actually serious) is uncertain. We therefore conclude that the 
responsibilities of researchers to avoid unnecessary harm to 
significant numbers of participants and disruption to publicly-
funded health services mean that radiographer flagging (result-
ing in far fewer false positives while missing a small number of 
true positives with unclear benefit of earlier diagnosis) constitutes 
an ethically more justified approach in the UK Biobank imaging 
study than systematic radiologist review. Some might argue that 
concerns about generating false positives suggest the case for 
a policy of no feedback of any IFs. However, in the light of 
legal advice regarding the duty of care it owed to participants, 
UK Biobank decided not to withhold all feedback on potentially 
serious IFs, but to minimize the generation of false positives by 
only feeding back potentially serious IFs which are also con-
firmed by a radiologist. This approach should be seen within the 
context of large-scale, population based imaging of healthy 
volunteers; a different approach may well be appropriate for other 
types of imaging studies, which may be smaller, based in clinical 
centres, have a different duty of care between research 
participants and researchers, or include participants with different 
characteristics (e.g., age) to those in the UK Biobank study.
While our underlying objective was to test the IFs protocol for 
the UK Biobank imaging study, our findings are of potential rel-
evance in other contexts in which individuals are imaged prior to 
clinical presentation of disease, including public health and com-
mercial screening. In both situations, it is important to consider 
the potential benefits of making a true positive diagnosis versus 
the potential harms to the individual and to publicly-funded health 
services, of a false positive diagnosis. The significant number 
of false positives generated by systematic radiologist report-
ing in our study implies that imaging of asymptomatic people 
should not be undertaken without appropriate concern for ensur-
ing that the individuals being imaged do not end up worse off 
than they started.
Strengths
Our study is the first to systematically follow up all participants 
receiving feedback about IFs and their GPs, giving the most 
comprehensive data on the impact of feedback of potentially 
serious IFs in any research imaging study to date and providing 
the first quantitative comparison of two different protocols for 
handling IFs. We have demonstrated for the first time the much 
lower rates of potentially serious IFs and, most importantly, false 
positives detected with a protocol in which radiologists report 
only those images which radiographers flag as having poten-
tially serious IFs. Although the public support the principle of 
providing feedback of IFs12, regardless of clinical severity10, most 
previous studies did not survey people who had actually received 
feedback. Our findings are crucial to informing future policy 
surrounding feedback of IFs in research studies.
Our study was strengthened by good questionnaire response 
rates and near complete data on final diagnoses due to extensive 
efforts to gather these directly from participants and their GPs, 
and data collection at both early and later time periods following 
feedback. Results related to understanding of consent and impact 
of feedback on participants were confirmed and contextualised 
in a parallel, qualitative study.
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Limitations
Radiographer flagging rates could, in principle, have been influ-
enced by a relative lack of experience with the first 1000 imaged 
participants, or by knowledge that radiologists were also review-
ing all images. However, ongoing collection of data on potentially 
serious IFs in the 7000 participants imaged subsequently showed 
the prevalence of IFs detected by radiographers to be broadly 
consistent over time with a stable prevalence of potentially seri-
ous IFs confirmed by radiologists (mean proportion of 1.7%) 
(Supplementary File 10).
Although questionnaire response rates by participants were 
generally high, only around two thirds of participants’ GPs 
responded about participants’ emotional well-being and over-
all net benefit/harm. The design of the questionnaires did not 
allow for quantification of the use of particular health services or 
evaluation of the associated costs. However, UK Biobank con-
tinues to collect data from participants with potentially serious 
IFs and their GPs through questionnaires, supplemented by 
linkages to national health datasets. This will enable further 
clinical, health economic and policy issues to be addressed using 
data from larger numbers of imaged participants.
Classification of final diagnoses as serious or not was based 
on clinical judgement of data available up to around six months 
following feedback of a potentially serious IF. Final diagnoses 
classified as serious may not actually shorten life span, or sub-
stantially impact on major body functions or quality of life in the 
21 participants concerned, who were apparently healthy at the 
time of their imaging visits. Some potentially serious IFs may 
take longer than six months to diagnose, or for their full impact to 
become clear, potentially leading to an incomplete picture of the 
adverse impacts of feedback.
Conclusions
The handling of potentially serious IFs merits serious consid-
eration by researchers undertaking imaging research studies. Our 
data provide evidence to inform policy for large-scale research 
imaging in healthy populations, and are relevant to asymptomatic 
populations undergoing public health screening and commercial 
imaging. They demonstrate that systematic radiologist review 
of all images leads to the diagnosis of previously unknown seri-
ous disease in some participants. However, the great majority of 
these findings turn out not to be serious, resulting in unnecessary 
anxiety for the participant and unnecessary clinical assessment, 
which may include invasive procedures, provided by publicly-
funded health services. Further, for those participants whose 
IFs do turn out to be serious, it is often difficult to ascertain whether 
this knowledge results in clear clinical benefit.
There is no ‘one-size-fits-all’ approach to handling IFs, as much 
depends on the purpose of the imaging, be that research, screening, 
or clinical care. In research studies of healthy volunteers, for 
whom there is no direct benefit for taking part, it is particularly 
critical to minimise harm. Based on these results, we suggest that 
this is achieved in an imaging study of UK Biobank’s scale and 
complexity with a protocol in which radiographers flag suspi-
cious images for reporting by radiologists, rather than systematic 
review of all images by radiologists.
Data availability
Due to the confidential nature of questionnaire responses and 
clinical information on participants with potentially serious 
incidental findings, it is not possible to publicly share all of the 
data on which our analyses were based, but extensive summaries 
of all relevant data are included in the supplementary material and 
within the linked online material.
Importantly, any bona fide researcher can apply to use the UK 
Biobank resource, with no preferential or exclusive access, for 
health related research that is in the public interest. Application for 
access to UK Biobank data involves registration and application via 
the UK Biobank website, with applications considered by the UK 
Biobank Access Sub-Committee. Following approval, research-
ers and their institutions sign a Material Transfer Agreement and 
pay modest access charges. Further information on applying to 
access UK Biobank data is available at: http://www.ukbiobank.
ac.uk/register-apply/.
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 interpretation,” and whether such training would alter the outcomes. Some indications are given (from the
group’s experience beyond the first 1000), but competency gained from formal directed training may be
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literature .
It is not quite clear what is meant by: “We reconciled multiple responses on similar items from the three
questionnaires by prioritising ‘yes’ responses and included data from coding of free text responses.”
Careful reading explains this, but the authors may want to help the reader here.
The ethical assessment is limited to the principle of non-maleficence. One could argue that this is a
surprisingly narrow ethical analysis. Other issues, such as in professional ethics (with basis in
deontological or virtue ethics), could easily be argued to be relevant as well. Moreover, the authors briefly
mention the alternative of not returning information on IFs as part of this type of research (the UK Biobank
imaging study), but refer to “legal advice” and “duty of care” to conclude that return of IFs are warranted.
Given their findings (e.g., on lack of benefit and altruistic motivations), this conclusion may not be as
obvious as the authors think and may need more elaboration to convince readers who are not part of or
familiar to the project. Moreover, it also justifies some reflection on the relationship between legal and
moral considerations. It is clear that this is not an article on the ethics of IFs, but when addressing ethical
issues, which I strongly endorse, this should be done somewhat more elaborate.
In general this is a well-planned and well-conducted study with interesting results that will make a nice
reference in the field.
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